Stem Cell Therapy Market with 8.18% CAGR : Industry Analysis By Future Demand, Top Players, Revenue and Growth Rate Through 2027 | 112 Report Pages -…

The size of the global Stem Cell Therapy market was estimated to be USD 11910.63 in 2021 and to increase to USD 19090.47 by 2028, with a forecasted CAGR of 8.18%. The majority of companies [Pharmicell Co., Ltd, MEDIPOST Co., Ltd., Nuvasive, Inc., RTI Surgical, Inc., Holostem Terapie Avanzate S.r.l., Cytori Therapeutics, Fibrocell Science, Inc., Osiris Therapeutics, Inc., Promethera Biosciences, RTI Surgical, Inc, Celgene Corporation, Anterogen Co., Ltd.] discussed in the report have focused on expansion, investment, acquisitions, delivery focus, portfolio expansion, and brand development.

Stem Cell Therapy Market Insights 2022 By Types (Adult Stem Cells, Human Embryonic, Induced Pluripotent Stem Cells, Very Small Embryonic Like Stem Cells), Applications (Regenerative Medicine, Drug Discovery and Development), By Segmentation, Regions and Forecast to 2028. The Global Stem Cell Therapy market Report provides In-depth analysis on the market status of the Stem Cell Therapy Top manufacturers with best facts and figures, meaning, Definition, SWOT and PESTAL analysis, expert opinions and the latest developments across the globe., the Stem Cell Therapy Market Report contains Full TOC, Tables and Figures, and Chart with Key Analysis, Pre and Post COVID-19 Market Outbreak Impact Analysis and Situation by Regions.

Stem Cell Therapy Market Research Report is spread across 112 Pages and provides exclusive data, information, vital statistics, trends, and competitive landscape details in this niche sector.

The global Stem Cell Therapy market size was valued at USD 11910.63 million in 2021 and is expected to expand at a CAGR of 8.18% during the forecast period, reaching USD 19090.47 million by 2027.

Stem-cell therapy is the use of stem cells to treat or prevent a disease or condition.Bone marrow transplant is the most widely used stem-cell therapy, but some therapies derived from umbilical cord blood are also in use. Research is underway to develop various sources for stem cells, and to apply stem-cell treatments for neurodegenerative diseases and conditions, diabetes, heart disease, and other conditions.With the ability of scientists to isolate and culture embryonic stem cells, and with scientists growing ability to create stem cells using somatic cell nuclear transfer and techniques to create induced pluripotent stem cells, controversy has crept in, both related to abortion politics and to human cloning. Additionally, efforts to market treatments based on transplant of stored umbilical cord blood have been controversial.

The report combines extensive quantitative analysis and exhaustive qualitative analysis, ranges from a macro overview of the total market size, industry chain, and market dynamics to micro details of segment markets by type, application and region, and, as a result, provides a holistic view of, as well as a deep insight into the Stem Cell Therapy market covering all its essential aspects.

For the competitive landscape, the report also introduces players in the industry from the perspective of the market share, concentration ratio, etc., and describes the leading companies in detail, with which the readers can get a better idea of their competitors and acquire an in-depth understanding of the competitive situation. Further, mergers and acquisitions, emerging market trends, the impact of COVID-19, and regional conflicts will all be considered.

In a nutshell, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the market in any manner.

The Global Stem Cell Therapy market is anticipated to rise at a considerable rate during the forecast period, between 2022 and 2028. In 2021, the market is growing at a steady rate and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Final Report will add the analysis of the impact of COVID-19 And Russia Ukraine War on this industry.

TO KNOW HOW COVID-19 PANDEMIC AND RUSSIA UKRAINE WAR WILL IMPACT THIS MARKET REQUEST SAMPLE

Moreover, it helps new businesses perform a positive assessment of their business plans because it covers a range of topics market participants must be aware of to remain competitive.

Stem Cell Therapy Market Report identifies various key players in the market and sheds light on their strategies and collaborations to combat competition. The comprehensive report provides a two-dimensional picture of the market. By knowing the global revenue of manufacturers, the global price of manufacturers, and the production by manufacturers during the forecast period of 2022 to 2028, the reader can identify the footprints of manufacturers in the Stem Cell Therapy industry.

Get a Sample PDF of report https://www.360researchreports.com/enquiry/request-sample/21612397

As well as providing an overview of successful marketing strategies, market contributions, and recent developments of leading companies, the report also offers a dashboard overview of leading companies past and present performance. Several methodologies and analyses are used in the research report to provide in-depth and accurate information about the Stem Cell Therapy Market.

Which are the prominent Stem Cell Therapy Market players across the globe?

The current market dossier provides market growth potential, opportunities, drivers, industry-specific challenges and risks market share along with the growth rate of the global Stem Cell Therapy market. The report also covers monetary and exchange fluctuations, import-export trade, and global market

status in a smooth-tongued pattern. The SWOT analysis, compiled by industry experts, Industry Concentration Ratio and the latest developments for the global Stem Cell Therapy market share are covered in a statistical way in the form of tables and figures including graphs and charts for easy understanding.

Get a Sample Copy of the Stem Cell Therapy Market Report 2022

A thorough evaluation of the restrains included in the report portrays the contrast to drivers and gives room for strategic planning. Factors that overshadow the market growth are pivotal as they can be understood to devise different bends for getting hold of the lucrative opportunities that are present in the ever-growing market. Additionally, insights into market experts opinions have been taken to understand the market better.

Report further studies the market development status and future Stem Cell Therapy Market trend across the world. Also, it splits Stem Cell Therapy market Segmentation by Type and by Applications to fully and deeply research and reveal market profile and prospects.

On the basis of product type this report displays the production, revenue, price, market share and growth rate of each type, primarily split into:

On the basis of the end users/applications this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including:

Stem Cell Therapy Market Regional Analysis:

Which region is expected to hold the highest market share in the Stem Cell Therapy Market?

Geographically, this report is segmented into several key regions, with sales, revenue, market share and growth Rate of Stem Cell Therapy in these regions, from 2015 to 2027, covering

This Stem Cell Therapy Market Research/Analysis Report Contains Answers to your following Questions

Our research analysts will help you to get customized details for your report, which can be modified in terms of a specific region, application or any statistical details. In addition, we are always willing to comply with the study, which triangulated with your own data to make the market research more comprehensive in your perspective.

Inquire more and share questions if any before the purchase on this report at https://www.360researchreports.com/enquiry/pre-order-enquiry/21612397

With tables and figures helping analyse worldwide Global Stem Cell Therapy market trends, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Table of Content

1 Stem Cell Therapy Market Overview 1.1 Product Overview and Scope of Stem Cell Therapy Market 1.2 Stem Cell Therapy Market Segment by Type 1.2.1 Global Stem Cell Therapy Market Sales Volume and CAGR (%) Comparison by Type (2017-2027) 1.3 Global Stem Cell Therapy Market Segment by Application 1.3.1 Stem Cell Therapy Market Consumption (Sales Volume) Comparison by Application (2017-2027) 1.4 Global Stem Cell Therapy Market, Region Wise (2017-2027) 1.4.1 Global Stem Cell Therapy Market Size (Revenue) and CAGR (%) Comparison by Region (2017-2027) 1.4.2 United States Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.3 Europe Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.4 China Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.5 Japan Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.6 India Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.7 Southeast Asia Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.8 Latin America Stem Cell Therapy Market Status and Prospect (2017-2027) 1.4.9 Middle East and Africa Stem Cell Therapy Market Status and Prospect (2017-2027) 1.5 Global Market Size of Stem Cell Therapy (2017-2027) 1.5.1 Global Stem Cell Therapy Market Revenue Status and Outlook (2017-2027) 1.5.2 Global Stem Cell Therapy Market Sales Volume Status and Outlook (2017-2027) 1.6 Global Macroeconomic Analysis 1.7 The impact of the Russia-Ukraine war on the Stem Cell Therapy Market

2 Industry Outlook 2.1 Stem Cell Therapy Industry Technology Status and Trends 2.2 Industry Entry Barriers 2.2.1 Analysis of Financial Barriers 2.2.2 Analysis of Technical Barriers 2.2.3 Analysis of Talent Barriers 2.2.4 Analysis of Brand Barrier 2.3 Stem Cell Therapy Market Drivers Analysis 2.4 Stem Cell Therapy Market Challenges Analysis 2.5 Emerging Market Trends 2.6 Consumer Preference Analysis 2.7 Stem Cell Therapy Industry Development Trends under COVID-19 Outbreak 2.7.1 Global COVID-19 Status Overview 2.7.2 Influence of COVID-19 Outbreak on Stem Cell Therapy Industry Development

3 Global Stem Cell Therapy Market Landscape by Player 3.1 Global Stem Cell Therapy Sales Volume and Share by Player (2017-2022) 3.2 Global Stem Cell Therapy Revenue and Market Share by Player (2017-2022) 3.3 Global Stem Cell Therapy Average Price by Player (2017-2022) 3.4 Global Stem Cell Therapy Gross Margin by Player (2017-2022) 3.5 Stem Cell Therapy Market Competitive Situation and Trends 3.5.1 Stem Cell Therapy Market Concentration Rate 3.5.2 Stem Cell Therapy Market Share of Top 3 and Top 6 Players 3.5.3 Mergers and Acquisitions, Expansion

4 Global Stem Cell Therapy Sales Volume and Revenue Region Wise (2017-2022) 4.1 Global Stem Cell Therapy Sales Volume and Market Share, Region Wise (2017-2022) 4.2 Global Stem Cell Therapy Revenue and Market Share, Region Wise (2017-2022) 4.3 Global Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.4 United States Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.4.1 United States Stem Cell Therapy Market Under COVID-19 4.5 Europe Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.5.1 Europe Stem Cell Therapy Market Under COVID-19 4.6 China Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.6.1 China Stem Cell Therapy Market Under COVID-19 4.7 Japan Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.7.1 Japan Stem Cell Therapy Market Under COVID-19 4.8 India Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.8.1 India Stem Cell Therapy Market Under COVID-19 4.9 Southeast Asia Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.9.1 Southeast Asia Stem Cell Therapy Market Under COVID-19 4.10 Latin America Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.10.1 Latin America Stem Cell Therapy Market Under COVID-19 4.11 Middle East and Africa Stem Cell Therapy Sales Volume, Revenue, Price and Gross Margin (2017-2022) 4.11.1 Middle East and Africa Stem Cell Therapy Market Under COVID-19

5 Global Stem Cell Therapy Sales Volume, Revenue, Price Trend by Type 5.1 Global Stem Cell Therapy Sales Volume and Market Share by Type (2017-2022) 5.2 Global Stem Cell Therapy Revenue and Market Share by Type (2017-2022) 5.3 Global Stem Cell Therapy Price by Type (2017-2022) 5.4 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate by Type (2017-2022) 5.4.1 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate of Adult Stem Cells (2017-2022) 5.4.2 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate of Human Embryonic (2017-2022) 5.4.3 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate of Induced Pluripotent Stem Cells (2017-2022) 5.4.4 Global Stem Cell Therapy Sales Volume, Revenue and Growth Rate of Very Small Embryonic Like Stem Cells (2017-2022)

6 Global Stem Cell Therapy Market Analysis by Application 6.1 Global Stem Cell Therapy Consumption and Market Share by Application (2017-2022) 6.2 Global Stem Cell Therapy Consumption Revenue and Market Share by Application (2017-2022) 6.3 Global Stem Cell Therapy Consumption and Growth Rate by Application (2017-2022) 6.3.1 Global Stem Cell Therapy Consumption and Growth Rate of Regenerative Medicine (2017-2022) 6.3.2 Global Stem Cell Therapy Consumption and Growth Rate of Drug Discovery and Development (2017-2022)

7 Global Stem Cell Therapy Market Forecast (2022-2027) 7.1 Global Stem Cell Therapy Sales Volume, Revenue Forecast (2022-2027) 7.1.1 Global Stem Cell Therapy Sales Volume and Growth Rate Forecast (2022-2027) 7.1.2 Global Stem Cell Therapy Revenue and Growth Rate Forecast (2022-2027) 7.1.3 Global Stem Cell Therapy Price and Trend Forecast (2022-2027) 7.2 Global Stem Cell Therapy Sales Volume and Revenue Forecast, Region Wise (2022-2027) 7.2.1 United States Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.2 Europe Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.3 China Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.4 Japan Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.5 India Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.6 Southeast Asia Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.7 Latin America Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.2.8 Middle East and Africa Stem Cell Therapy Sales Volume and Revenue Forecast (2022-2027) 7.3 Global Stem Cell Therapy Sales Volume, Revenue and Price Forecast by Type (2022-2027) 7.3.1 Global Stem Cell Therapy Revenue and Growth Rate of Adult Stem Cells (2022-2027) 7.3.2 Global Stem Cell Therapy Revenue and Growth Rate of Human Embryonic (2022-2027) 7.3.3 Global Stem Cell Therapy Revenue and Growth Rate of Induced Pluripotent Stem Cells (2022-2027) 7.3.4 Global Stem Cell Therapy Revenue and Growth Rate of Very Small Embryonic Like Stem Cells (2022-2027) 7.4 Global Stem Cell Therapy Consumption Forecast by Application (2022-2027) 7.4.1 Global Stem Cell Therapy Consumption Value and Growth Rate of Regenerative Medicine(2022-2027) 7.4.2 Global Stem Cell Therapy Consumption Value and Growth Rate of Drug Discovery and Development(2022-2027) 7.5 Stem Cell Therapy Market Forecast Under COVID-19

8 Stem Cell Therapy Market Upstream and Downstream Analysis 8.1 Stem Cell Therapy Industrial Chain Analysis 8.2 Key Raw Materials Suppliers and Price Analysis 8.3 Manufacturing Cost Structure Analysis 8.3.1 Labor Cost Analysis 8.3.2 Energy Costs Analysis 8.3.3 RandD Costs Analysis 8.4 Alternative Product Analysis 8.5 Major Distributors of Stem Cell Therapy Analysis 8.6 Major Downstream Buyers of Stem Cell Therapy Analysis 8.7 Impact of COVID-19 and the Russia-Ukraine war on the Upstream and Downstream in the Stem Cell Therapy Industry

9 Players Profiles 9.1 Pharmicell Co., Ltd 9.1.1 Pharmicell Co., Ltd Basic Information, Manufacturing Base, Sales Region and Competitors 9.1.2 Stem Cell Therapy Product Profiles, Application and Specification 9.1.3 Pharmicell Co., Ltd Market Performance (2017-2022) 9.1.4 Recent Development 9.1.5 SWOT Analysis 9.2 MEDIPOST Co., Ltd. 9.2.1 MEDIPOST Co., Ltd. Basic Information, Manufacturing Base, Sales Region and Competitors 9.2.2 Stem Cell Therapy Product Profiles, Application and Specification 9.2.3 MEDIPOST Co., Ltd. Market Performance (2017-2022) 9.2.4 Recent Development 9.2.5 SWOT Analysis 9.3 Nuvasive, Inc. 9.3.1 Nuvasive, Inc. Basic Information, Manufacturing Base, Sales Region and Competitors 9.3.2 Stem Cell Therapy Product Profiles, Application and Specification 9.3.3 Nuvasive, Inc. Market Performance (2017-2022) 9.3.4 Recent Development 9.3.5 SWOT Analysis 9.4 RTI Surgical, Inc. 9.4.1 RTI Surgical, Inc. Basic Information, Manufacturing Base, Sales Region and Competitors 9.4.2 Stem Cell Therapy Product Profiles, Application and Specification 9.4.3 RTI Surgical, Inc. Market Performance (2017-2022) 9.4.4 Recent Development 9.4.5 SWOT Analysis 9.5 Holostem Terapie Avanzate S.r.l. 9.5.1 Holostem Terapie Avanzate S.r.l. Basic Information, Manufacturing Base, Sales Region and Competitors 9.5.2 Stem Cell Therapy Product Profiles, Application and Specification 9.5.3 Holostem Terapie Avanzate S.r.l. Market Performance (2017-2022) 9.5.4 Recent Development 9.5.5 SWOT Analysis 9.6 Cytori Therapeutics 9.6.1 Cytori Therapeutics Basic Information, Manufacturing Base, Sales Region and Competitors 9.6.2 Stem Cell Therapy Product Profiles, Application and Specification 9.6.3 Cytori Therapeutics Market Performance (2017-2022) 9.6.4 Recent Development 9.6.5 SWOT Analysis 9.7 Fibrocell Science, Inc. 9.7.1 Fibrocell Science, Inc. Basic Information, Manufacturing Base, Sales Region and Competitors 9.7.2 Stem Cell Therapy Product Profiles, Application and Specification 9.7.3 Fibrocell Science, Inc. Market Performance (2017-2022) 9.7.4 Recent Development 9.7.5 SWOT Analysis 9.8 Osiris Therapeutics, Inc. 9.8.1 Osiris Therapeutics, Inc. Basic Information, Manufacturing Base, Sales Region and Competitors 9.8.2 Stem Cell Therapy Product Profiles, Application and Specification 9.8.3 Osiris Therapeutics, Inc. Market Performance (2017-2022) 9.8.4 Recent Development 9.8.5 SWOT Analysis 9.9 Promethera Biosciences 9.9.1 Promethera Biosciences Basic Information, Manufacturing Base, Sales Region and Competitors 9.9.2 Stem Cell Therapy Product Profiles, Application and Specification 9.9.3 Promethera Biosciences Market Performance (2017-2022) 9.9.4 Recent Development 9.9.5 SWOT Analysis 9.10 RTI Surgical, Inc 9.10.1 RTI Surgical, Inc Basic Information, Manufacturing Base, Sales Region and Competitors 9.10.2 Stem Cell Therapy Product Profiles, Application and Specification 9.10.3 RTI Surgical, Inc Market Performance (2017-2022) 9.10.4 Recent Development 9.10.5 SWOT Analysis 9.11 Celgene Corporation 9.11.1 Celgene Corporation Basic Information, Manufacturing Base, Sales Region and Competitors 9.11.2 Stem Cell Therapy Product Profiles, Application and Specification 9.11.3 Celgene Corporation Market Performance (2017-2022) 9.11.4 Recent Development 9.11.5 SWOT Analysis 9.12 Anterogen Co., Ltd. 9.12.1 Anterogen Co., Ltd. Basic Information, Manufacturing Base, Sales Region and Competitors 9.12.2 Stem Cell Therapy Product Profiles, Application and Specification 9.12.3 Anterogen Co., Ltd. Market Performance (2017-2022) 9.12.4 Recent Development 9.12.5 SWOT Analysis

10 Research Findings and Conclusion

11 Appendix 11.1 Methodology 11.2 Research Data Source

Purchase this report (Price 3250 USD for a single-user license) https://www.360researchreports.com/purchase/21612397

About Us:

Market is changing rapidly with the ongoing expansion of the industry. Advancement in the technology has provided todays businesses with multifaceted advantages resulting in daily economic shifts. Thus, it is very important for a company to comprehend the patterns of the market movements in order to strategize better. An efficient strategy offers the companies with a head start in planning and an edge over the competitors. 360 Research Reports is the credible source for gaining the market reports that will provide you with the lead your business needs.

Contact Us: Web : https://360researchreports.com/ Email: [emailprotected] Organization: 360 Research Reports Phone: +44 20 3239 8187/ +14242530807

Press Release Distributed by The Express Wire

To view the original version on The Express Wire visit Stem Cell Therapy Market with 8.18% CAGR : Industry Analysis By Future Demand, Top Players, Revenue and Growth Rate Through 2027 | 112 Report Pages

See original here:
Stem Cell Therapy Market with 8.18% CAGR : Industry Analysis By Future Demand, Top Players, Revenue and Growth Rate Through 2027 | 112 Report Pages -...

Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy – Marketscreener.com

JCR Pharmaceuticals Co., Ltd. and Sysmex Corporation announced that they have established a joint venture (hereafter the "joint venture") for carrying out research and development, manufacture and sales of cell-based regenerative medicine products including hematopoietic stem cells and other stem cells. In recent years, the significant potential of regenerative medicine and cell therapy have been established in particular in areas that have traditionally been difficult to address with conventional chemically synthesized low molecular weight drugs1 or biopharmaceuticals2, such as the restoration of tissues and functions lost as a result of aging, illness, autoimmune diseases, or cancer. In particular, research and development on the therapeutic application of stem cells including hematopoietic stem cells, mesenchymal stem cells, and iPS cells have generated significant attention. Since its inception, JCR has been engaged in the research, development, manufacturing and sales of pharmaceutical products using regenerative medicine, genetic engineering, and gene therapy technologies to advance therapies in the rare disease field. This is exemplified in the field of regenerative medicine, by the approval of TEMCELL HS Inj.3, the first allogeneic regenerative medicine in Japan (Non-proprietary name: Human (allogeneic) bone marrow-derived mesenchymal stem cells) in February 2016 for the treatment of acute graft-versus-host disease (acute GVHD)4, a serious complication that develops after hematopoietic stem cell transplantation. In recent years, JCR has further streamlined and integrated its expertise around the establishment of groundbreaking medicines for the advancement of highly innovative medicines that could not be developed without such groundbreaking technologies. In the joint venture, the two companies aim to realize the social implementation of regenerative medicine and cell therapy by integrating JCR's expertise in developing, manufacturing and marketing regenerative medicine products, with Sysmex's expertise in quality control testing technology and knowledge of workflows efficiency using robotics technology, including IoT. AlliedCel Corporation, which is the corporate name of the joint venture following prior discussions regarding the alliance both companies, was established on October 3, 2022. The joint venture will advance programs of the potential for technology development and commercialization, including the project currently being promoted by both companies using hematopoietic stem cell proliferation technology. The name AlliedCel stands for the joint venture's aspiration to integrate knowledge and expertise from a broad set of collaborators and stakeholders including business partners, patients and their families, with the united goal of unleashing the power of cells in supporting patients in their need for life-changing therapies. Through the research and development of regenerative medicine products using diverse cells such as stem cells, AlliedCel aims to provide appropriate treatment options to patients and improve their prognosis.

View post:
Jcr Pharmaceuticals Co., Ltd. and Sysmex Establish A Joint Venture in the Field of Regenerative Medicine and Cell Therapy - Marketscreener.com

ANDREWS MEDICINE AND CELLTEX THERAPEUTICS CORPORATION JOIN FORCES TO BRING CUTTING EDGE TECHNOLOGIES TO ATHLETIC INJURIES – PR Newswire

HOUSTON, Oct. 4, 2022 /PRNewswire/ -- James R. "Jim" Andrews, MD, Chairman and CEO of Andrews Medicine of Pensacola, Florida, and David G. Eller, Chairman and CEO of Celltex Therapeutics Corporation of Houston, Texas, announced today that together they will form a new biotechnology company to bridge the divide between stem cell research and the current treatment of athletic injuries. The jointly owned company will operate under the name of "Andrews Celltex Biologics".

The new company will undertake the operation of a Sports Injury Program that includes the Celltex-sponsored FDA developmental study associated with its Investigational New Drug (IND) for the use of Celltex-produced autologous Mesenchymal Stem Cells (MSCs) in the treatment of orthopedic indications. Andrews Medicine will participate in this FDA observed IND research study and will be responsible for selection of participants and administration for this new study. The new venture promises to bring the best medical orthopedic practices of Andrews Medicine for treatment of sports injuries with best practices of Celltex for production of therapeutic quality autologous MSCsas a regenerative component of the treatment. Andrews Celltex Biologics will break new ground with this combined effort. The goal is an FDA approved Biologic License for this Celltex product.

Dr. Andrews said: "I have always known that stem cells, when properly handled, can add value to already effective treatments of inflammatory conditions caused by injury or disease. I am delighted that the FDA has been working with Celltex for studying the safety and efficacy of this combination of Celltex-produced MSCs with traditional medical treatment of multiple sports injury indications. Our know-how and network of sports teams and physicians will add immediate value to our new joint company. I am convinced that Andrews Celltex Biologics will be a leader in this huge growth sector of health care coupled with regenerative medicine."

"Celltex is excited about the opportunity to join forces with one of the best orthopedic and sports medicine companies in the country," said David G. Eller, Chairman and CEO of Celltex. "It is a perfect match. Surgical treatments coupled with Celltex-produced regenerative MSCs will improve recovery time and remediation. This joint effort of the two leading companies in their field will bring cutting edge regenerative health care for sports injuries and beyond."

David Eller continued, "Over the past 11 years, Celltex has developed unique know-how and proprietary technology to produce, in its specially designed cGMP lab, millions of MSCs from a small extraction of a person's adipose tissue. The integrity and vibrancy of the MSCs are of therapeutic quality. Over one trillion MSCs have been produced by Celltex, in its cGMP lab, from individuals wanting their own stem cells reintroduced into their bodies by medical doctors to fight a variety of diseases, especially those caused by inflammatory conditions. Given the autologous nature of Celltex-produced stem cells, there have been no severe adverse events when these stem cells have been reintroduced into the individuals from whom the small, one-time adipose tissue sample had been extracted."

ABOUT ANDREWS MEDICINE OF PENSACOLA, FLORIDA

Andrews Medicine is an integrated healthcare platform built on five decades of research, innovation, and clinical expertise led by internationally recognized orthopaedic surgeon, Dr. James "Jim" Andrews. Widely known as the surgeon for elite athletes from around the world, Dr. Andrews is also a pioneering thought leader in the field of research, injury prevention, new surgical techniques, and practice management. Andrews Medicine brings this experience and expertise to healthcare systems, medical providers, sports organizations, and the communities they serve, ensuring that every patient has access to exceptional clinical care. Read more at: http://www.andrewsmedicine.com

ABOUT CELLTEX THERAPEUTICS CORPORATION

Founded in 2011, Celltex Therapeutics Corporation is a Houston, Texas-based biotechnology company that specializes in the manufacturing and cryopreservation of Mesenchymal Stem Cells (MSCs).Celltex is a leading commercial provider of autologous MSCs for therapeutic use. The Company uses its proprietary technology to isolate, cryopreserve and culture billions of undifferentiated and genetically stable MSCs in its state-of-the-art current Good Manufacturing Practices (cGMP)-compliant laboratory.The Company is dedicated to pioneering technological breakthroughs in regenerative medicine. For more information see: http://www.celltexbank.com

SOURCE Celltex Therapeutics Corporation

Originally posted here:
ANDREWS MEDICINE AND CELLTEX THERAPEUTICS CORPORATION JOIN FORCES TO BRING CUTTING EDGE TECHNOLOGIES TO ATHLETIC INJURIES - PR Newswire

Second-Line BCL Treatment Landscape Shifts From ASCT to CAR T-Cell Therapy – Targeted Oncology

Hematologic malignancies have been impacted heavily by the introduction of chimeric antigen receptor (CAR) T-cell therapy, which has demonstrated long remission in major clinical trials and received approvals by the FDA. CAR T-cell therapy provides a new option for patients with relapsed/refractory B-cell lymphoma (BCL).

The current treatment landscape for patients with relapsed/refractory [BCL] looks extremely promising, thanks to the positive results from clinical trials and thus the subsequent FDA approvals of these therapeutics, Manali Kamdar, MD, associate professor of medicine-hematology and clinical director of lymphoma services at the University of Colorado Medicine in Aurora, said in an interview with the SOHO Daily News beforethe 10th Annual Meeting of the Society of Hematologic Oncology (SOHO 2022).

Kamdars presentation on September 30, 2022, at 1:40 pm during the conference concerns the question of when to use CAR T-cell therapy vs autologous stem cell transplant (ASCT) in patients with relapsed/refractory aggressive BCL. She says the 3 phase 3 studies of CAR T-cell products that were presented at the 2021 American Society of Hematology Annual Meeting and Exposition (ASH 2021) have made a major difference in answering this question for high-risk patients.

Patients with diffuse large BCL who relapse within 12 months of frontline chemoimmunotherapy with R-CHOP (rituximab [Rituxan], cyclophosphamide, doxorubicin, vincristine [Oncovin], prednisone) are considered primary refractory, and these patients have very poor outcomes. In the past, they would receive salvage chemotherapy followed by an ASCT. Kamdar says only a quarter of these high-risk patients would achieve long-term remission following ASCT.

This led to an urgent need for CAR T-cell therapy in the second line for these patients. CAR T cells had shown efficacy for R/R BCL, leading to the approval of these therapies in patients with at least 2 prior lines of treatment, the first being axicabtagene ciloleucel (axi-cel; Yescarta) in 2017.1,2

The results of 3 pivotal phase 3 trials of CAR T-cell products were first presented at ASH 2021, comparing them with salvage chemotherapy and ASCT in patients with aggressive non-Hodgkin BCL who relapsed within 12 months of frontline chemoimmunotherapy. The ZUMA-7 trial (NCT03391466) that evaluated axi-cel and the TRANSFORM trial (NCT03575351) that evaluated lisocabtagene maraleucel (liso-cel; Breyanzi) showed significantly higher event-free survival (EFS) rates in patients who received CAR T-cell therapy vs ASCT, but the BELINDA trial (NCT03570892) that evaluated tisagenlecleucel (tisa-cel; Kymriah) failed to show improved EFS over standard-of-care second-line therapy.3-5 Kamdar plans to discuss the possible reasons for the different outcomes of these trials in greater detail in her presentation.

With axi-cel and liso-cel receiving FDA approvals as second-line therapy, CAR T-cell therapy stands to replace ASCT in this stage of sequencing.6,7 Within this high-risk R/R large BCL subset, I will have to say I no longer recommend an ASCT based on these 2 positive studies, and that we take patients to CAR T-cell therapy, Kamdar said.

Kamdars presentation will focus on the outcomes demonstrated by these trials, including the statistically significant EFS, progression-free survival, and complete response rate of CAR T-cell therapy. Additionally, she will discuss the manageable levels of toxicity seen in the 2 positive trials, with no grade 4 or 5 cytokine release syndrome or neurotoxicity being reported. Longer follow-up is needed to observe overall survival outcomes and other long-term impacts of these therapies.

Despite these results, CAR T-cell therapy is not an option for those who are chemotherapy-sensitive who relapsed more than 12 months after frontline therapy. Currently, ASCT remains the standard of care, Kamdar said. But itd be nice to see [whether] there is something else that can actually be better.

Additionally, the role of CAR T-cell therapy is being investigated in patients who are transplant-ineligible in the phase 2 TRANSCEND-PILOT 017006 study (NCT03483103) that evaluates liso-cel. Durable responses to liso-cel were reported in the primary analysis presented at the 2022 American Society of Clinical Oncology Annual Meeting.8

For patients with high-risk R/R BCL, Kamdar says its crucial to start referring patients for CAR T-cell therapy as soon as they are determined to be primary refractory. CAR T-cell therapy is certainly a process that takes time, because manufacturing of the cells requires a minimum of 17 to 34 days based on the construct you choose, she said. Additionally, insurance approvals and logistical concerns can cause further delays to starting therapy. CAR T-cell production time and accessibility may be improved by new approaches that are being investigated, including allogeneic CAR T cells that do not require patients to undergo leukapheresis.

One rising area of need is therapies for patients who fail CAR T-cell therapy, who may have limited treatment options if they are CD19 negative. Kamdar anticipates that novel therapies, including bispecific antibodies, bispecific T-cell engagers, and natural killer T cells, could fill this unmet need in patients with R/R BCL. [Approximately] 20% of patients [in recent trials of bispecific agents] may have actually received prior CAR T-[cell therapy], and they are showing a response in patients who have failed prior CAR T-cell therapy, she said.

She suggests novel time-limited bispecific therapies will not only benefit those who relapsed or who cannot receive CAR T-cell therapy, but they are also valuable for physicians who want to treat patients while waiting to start CAR T-cell therapy.

Kamdar is looking forward to discussing the shift from ASCT to CAR T-cell therapy in second-line therapy in greater detail at SOHO 2022. Im very excited to see all my colleagues after so long, Kamdar said. Im thrilled to be able to connect in person with everyone. Its been too long.

REFERENCES:

1. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas.N Engl J Med. 2017;377(26):2545-2554. doi:10.1056/NEJMoa1708566

2. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma. News release. FDA; October 18, 2017. Updated March 21, 2018. Accessed August 25, 2022. https://bit.ly/3ANA0k5

3. Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma.N Engl J Med. 2022;386(7):640-654. doi:10.1056/NEJMoa2116133

4. Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022;399(10343):2294-2308. Published correction appears in Lancet. 2022;400(10347):160.

5. Bishop MR, Dickinson M, Purtill D, et al. Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma.N Engl J Med. 2022;386(7):629-639. doi:10.1056/NEJMoa2116596

6. FDA approves axicabtagene ciloleucel for second-line treatment of large B-cell lymphoma. FDA. April 1, 2022. Accessed August 25, 2022. https://bit.ly/3ANmZab

7. FDA approves lisocabtagene maraleucel for second-line treatment of large B-cell lymphoma. FDA. June 24, 2022. Accessed August 25, 2022. https://bit.ly/3Q52NVT

8. Seghal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel (liso-cel) as second-line (2L) therapy for R/R large B-cell lymphoma (LBCL) in patients (pt) not intended for hematopoietic stem cell transplantation (HSCT): primary analysis from the phase 2 PILOT study. J Clin Oncol. 2022;40(suppl 16):7062. doi:10.1200/JCO.2022.40.16_suppl.7062

Visit link:
Second-Line BCL Treatment Landscape Shifts From ASCT to CAR T-Cell Therapy - Targeted Oncology

Regenerative Medicine For Heart Diseases: How It Is Better Than Conventional Treatments | TheHealthSite.co – TheHealthSite

The future possibilities of regenerative Medicine are endless. Know how regenerative medicine for heart diseases is better than conventional treatments.

Written by Longjam Dineshwori | Updated : October 5, 2022 9:52 AM IST

In the past few days, news of people dying due to cardiac arrest and heart attack during the festivities have been making headlines. Concerningly, increasing number of younger people, precisely adults who are in their 30s, are getting heart problems today. Health experts have been advising people to maintain a healthy lifestyle to prevent heart diseases or at least delay their onset. Also, tremendous advancements have been made in the field of cardiology making treatment of heart ailments more effective and less invasive. One of them is regenerative medicine, which is now being explored for the treatment of several diseases.

Get to more about regenerative medicine and its possibilities for treating heart diseases from Dr Pradeep Mahajan, Regenerative Medicine Researcher, Stem Rx Bioscience Solutions Pvt. Ltd, Navi Mumbai.

An alarming one out of four deaths in our country today is due to heart disease. This is largely due to our sedentary lifestyles, unhealthy eating habits, and stress. Barring the heart conditions that are present from birth (congenital) or that are passed down through the generations (inherited), heart diseases can be prevented or at least the onset can be delayed by maintaining a healthy lifestyle.

The field of cardiology (relating to the heart) has advanced tremendously, and there are several medications and surgical procedures that help patients maintain the functions of the heart. However, these call for invasive treatments and the need for life-long medications. Moreover, the side effects of medicines should also be taken into account.

Enter the field of Regenerative Cardiology! As the word suggests, this branch refers to utilising the natural healing potential of the body to repair and re-grow damaged heart tissues. Stem cells have been researched in several heart diseases to overcome the damage to the heart and facilitate healing. Not just stem cells, but cell-based products like exosomes, molecular chaperones, growth factors etc. have shown promise as well. Do not think about the technicalities, all these molecules are present in our body and researchers and clinicians are now working on how to apply these for the treatment of several diseases.

Commonly, we hear of blocks in the heart, infection, and weak muscles of the heart that do not pump blood properly leading to various diseases. With cell-based therapies, we can tackle each of these issues. Stem cells (the most basic 'unspecialized' cells of our body) can multiply and form various cells of the body, including heart cells. Similarly, cell products like exosomes are cargo packets they carry the required substances for repair and re-growth of tissues. These biological molecules have 'housekeeping functions, meaning that they ensure that any unwanted product and even bacteria/viruses are removed periodically from the body.

The possibilities of Regenerative Medicine for heart diseases are many blocks in the heart can be dissolved, blood supply can be improved, heart muscles can be strengthened, etc. because these biological molecules are capable of reducing inflammation (swelling) in the body, modify the immune system to function better, enhance the functions of other cells, etc. Since these are part of our own body, providing these molecules in the appropriate quantity at the desired site will enhance healing without side effects. In fact, there is ongoing research on growing healthy heart tissue in labs with these biological molecules to transplant them into the human body. Who knows, someday the whole heart might be grown in a lab! While the future possibilities are endless, the current cell-based therapies can be a definitive addition to enhance the outcomes of existing conventional treatments. Of course, rehabilitation and lifestyle modifications are mandatory to maintain the results.

A holistic approach is important one cannot simply rely on symptom management the core issues have to be targeted and Regenerative Medicine can do just that. The death rate due to heart disease can be reduced and patients will be able to have a better quality of life.

Follow us on

More:
Regenerative Medicine For Heart Diseases: How It Is Better Than Conventional Treatments | TheHealthSite.co - TheHealthSite

HK Develops Precision Cure to Help Children with Blood Cancer Prolong Life – The Epoch Times

Children with acute myeloid leukemia (AML) who develop drug resistance generally lack treatment options and are deemed incurable. Recently, The CUHKs HK-HOPE developed a method to obtain the sensitivity of a patients cancer cells to a basket of targeted drugs within three days. In combination with genomic analyses, AML patients are matched with the most effective drugs according to their individual conditions.

AML is a rare but highly aggressive blood cancer that accounts for five percent of pediatric cancers. In Hong Kong, there are about 10 new cases per year. Chemotherapy with stem cell transplantation has remained the standard of care for decades. Advances in medical development have significantly improved the overall survival rate of newly diagnosed AMLpateints to 70 percent. However, the chance of survival drops below 40 percent for patients who develop relapses.

The research team of CUHKs HK-HOPE performed comprehensive drug and genomic profiling of bone marrow biopsies from 52 children with AML and integrated it with their clinical parameters to deliver the first high-dimensional gene-drug-clinical dataset. It has been made freely accessible to all researchers around the globe to stimulate further basic, translational and clinical research on this rare blood cancer.

From the dataset, the researchers also uncovered a children-specific pattern of drug response, linkage to genetic mutations, and active targeted agents with immediate clinical relevance. The study identified a wealth of targeted agents from an approved drug library showing better effectiveness over standard chemotherapeutics against pediatric leukemia. The findings enable the prioritization of new drugs to be tested in upcoming clinical trials.

Through the drug and genomic analysis, the team developed the first precision medicine for pediatric leukemia patients. This enables evidence-based drug selection for relapse cases that can extend patients survival or even cure the disease.

Professor Leung Kam Tong, Assistant Professor of the Department of Pediatrics at CU Medicine, said that with that testing method, they could obtain drug sensitivity testing results within three days. In combination with genomic analysis, they could match the correct drugs to individual leukemia patients who had no further treatment options in a timely manner, bringing hope to those sick kids.

Professor Li Chi Kong, Professor of the Department of Paediatrics at CUHKs Faculty of Medicine (CU Medicine), stated that a 14-year-old AML patient using the new precision medicine approach had experienced a relieving condition with his survival extended by two and a half years, fulfilling the patients wish.

After treatment, another 14-month-old patient also experienced disease remission with significantly prolonged survival.

Professor Albert Martin Li, Director of HK-HOPE and Chairman of CU Medicines Department of Pediatrics, added that they had successfully implemented precision medicine-guided management in childhood AML patients by making good use of valuable data and that the personalized medicine approach could be extended to other leukemia types.

The studys findings have been published in Blood Cancer Discovery, a journal of the American Association for Cancer Research.

See the rest here:
HK Develops Precision Cure to Help Children with Blood Cancer Prolong Life - The Epoch Times

Dr. Tania Small Appointed to the Board of Governors of the Accreditation Council for Medical Affairs – citybiz

Dr. Tania Small, MD

NEW YORK(BUSINESS WIRE)The Accreditation Council for Medical Affairs announces the appointment of Tania Small, MD, Global Head of Oncology Medical Affairs and Chair of R&D Diversity, Equity, and Inclusion Council at GSK, to its board of governors today.

The ACMA has both US and international presence in over 80 countries. It is highly recognized for its accredited board certification, and the Board-Certified Medical Affairs Specialist (BCMAS) program designed for pharmaceutical industry medical affairs and medical science liaison (MSL) professionals. Additionally, the ACMA is regarded as the pre-eminent thought leader in US and global medical affairs.

Through her leadership, Dr. Tania Small will make a significant contribution to the mission of ACAM as we continue to raise the bar for pharmaceutical executives with a focus on Medical Affairs and Medical Science Liaisons (MSLs).

We are honored to have Dr. Small join the ACMA Board. Tania is a highly respected professional in the life sciences industry. She is known for driving innovation that improves the experience and supports better outcomes of people living with cancer, said Dr. William Soliman, CEO and Founder of ACMA.

Dr. Small will play a critical role in helping to expand the mission of the ACMA in the life sciences industry. ACMA will continue to collaborate with the government, healthcare policy consortiums, pharmaceutical companies, and patient advocacy organizations to ensure that the ACMA continues to operate at the highest standards of ethics and compliance to achieve this broader mission.

I am honored to be joining the ACMA Board of Governors. They have been instrumental in positively shaping healthcare policy and dialogue. The ACMA is bringing forth a new era in the pharmaceutical industry by providing credible board certification for medical affairs / MSL professionals. An ACMA accreditation enhances MSL professionals ability to deliver upon their critical mission to healthcare providers and patients in need, said Dr. Small.

About Dr. Tania SmallTania Small, Global Head of Oncology Medical Affairs and Chair of R&D Diversity, Equity, and Inclusion Council at GSK, has built and leads an organization of medical professionals focused on patient-driven science. She is passionate about creating groundbreaking solutions that will successfully deliver transformational medicines and access mechanisms, which are needed to revolutionize both the experience and outcomes of people living with cancer and their treatment teams.

A board-certified pediatric hematologist/oncologist, Dr. Small has deep experience in clinical research and drug development. She was trained in hematology/oncology and bone marrow transplantation at Columbia University, where she also completed a genetic research fellowship. She subsequently continued her focus on both hematology and stem cell transplant at New York Presbyterian Hospital and received several grants for her translational research in gene therapy and regenerative medicine.

In previous roles with Novartis Oncology and Ipsen, Dr. Small successfully led the launch of multiple oncology therapies while overseeing programs for both clinical development and medical affairs. She has also led many patient-centered and diversity programs, working closely with the US FDA, Congress, and the American Society of Clinical Oncology (ASCO) to improve the diversity of enrollment in oncology clinical trials and elderly programs.

About Accreditation Council for Medical Affairs (ACMA)The Accreditation Council for Medical Affairs (ACMA) is highly regarded for its Board-Certified Medical Affairs Specialist (BCMAS) program. It is the worlds first and only board certification for MSL and medical affairs professionals. The ACMA offers a 360 suite of digital solutions for the life sciences industry, including market research, sentiment analysis, CRM tools, and more. The ACMA has the first ever Prior Authorization Certification Specialist (PACS) program to help streamline healthcare insurance hurdles. For more information, visit:www.medicalaffairsspecialist.org

More:
Dr. Tania Small Appointed to the Board of Governors of the Accreditation Council for Medical Affairs - citybiz

Mesenchymal stem cells market is projected to grow at a CAGR of 13.82% by 2032: Visiongain Research Inc – GlobeNewswire

Visiongain has published a new report entitled Mesenchymal Stem Cells Market 2022-2032. It includes profiles of Mesenchymal Stem Cells Market and Forecasts Market Segment by Type {Product (Cell & Cell Lines, Kits Media & Reagents, Others), Services}, Market segment by Source (Bone Marrow, Adipose Tissue, Cord Blood, fallopian Tube, Fetal Liver, Lung, Peripheral Blood, Other Sources), Market Segment by Indication (Bone & Cartilage Repair, cardiovascular Disease, Cancer, GvHD, Inflammatory & Immunological Diseases, Liver Diseases, Other Diseases), Market Segment by Application (Disease Modelling, Drug Discovery & Development, Stem Cell Banking, Tissue Engineering, Toxicology Studies, Other Applications) plus COVID-19 Impact Analysis and Recovery Pattern Analysis (V-shaped, W-shaped, U-shaped, L-shaped), Profiles of Leading Companies, Region and Country.

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

Rising Awareness About Therapeutic Potential of Mesenchymal Stem Cells The mesenchymal stem cell (MSC) market has a huge potential for expansion as it's the most prevalent stem cell type used in regenerative medicine. MSCs are now the most commonly used stem cell type in clinical trials and the most researched stem cell type in the scientific literature. MSC-based therapies are also gaining popularity due to the rapidly aging population and rising prevalence of chronic diseases. Mesenchymal Stem cells play a significant role in effective management of disease and research initiatives in specialized areas such as genomic testing and personalized medicine. As a result of rising awareness of the therapeutic potential of stem cells and the scarcity of effective therapeutic treatments for rare diseases there is rise in investment leading to the growth of the market, however significant operational cost associated with the mesenchymal stem cell expansion and banking is anticipated to hinder the market growth.

Download Exclusive Sample of Report @

Mesenchymal Stem Cells Market Report 2022-2032

How has COVID-19 had a Significant Negative Impact on the Mesenchymal Stem Cells Market?

The biotechnology industry has experienced evolutionary changes with regards to the operational management. Typical biopharmaceutical companies manufacturing products for mesenchymal stem cell development had a better response to staff disruptions and challenges evolving due to COVID-19.

There was an impact on the research & development activities and clinical trials as there were interruptions in the new patient enrolment for the active clinical trial. However, the business focused on inventing new therapies for the treatment of COVID-19 disease. In the past years, MSCs have established itself to be an effective technique to treat pulmonary disease, including COVID-19. MSC derived stem cell therapies have showed the potential for the treatment of the Covid 19 disease. Therefore, an increase in the number of clinical trials using MSCs has been observed. Countries such as the US, the UK, Belgium, France, Spain and Mexico are conducting clinical trials with mesenchymal stem cells to be used in the treatment of COVID-19.

How will this Report Benefit you?

Visiongains 281-page report provides 117 tables and 184 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the mesenchymal stem cells market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Mesenchymal Stem Cells Market. Get financial analysis of the overall market and different segments including type, Source, Indication, Application, and company size and capture higher market share. We believe that there are strong opportunities in this fast-growing mesenchymal stem cells market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

MSCs in the Development of Engineered Tissues and Organs hMSCs are considered as one of the prominent bio fabrication materials for decades as they are proved safe and effective in treating various injuries and diseases such as bone or cartilage regeneration, stroke & cancer. Bioprinting is a rapidly expanding tissue engineering area with a lot of promise for product customization and addressing the global tissue and organ scarcity, with a global market of $1.82 billion USD predicted by 2022. hMSCs have also been found to be capable of being guided toward hepatocyte differentiation thus indicating huge demand for hMSCs as tissue engineering of organ develops. The requirement for hMSC in engineered tissue and organ applications is, of course, reliant on cell generation, differentiation, and maturation technologies for the parenchymal cells required for organ function and thus it is expected that the increased availability of hMSC sources as a result of manufacturing technology advancements will pave the way for quick improvement and growth of the mesenchymal stem cells market.

Rise in Focus Towards Regenerative Medicine Therapies MSCs are a good cell source for tissue regeneration because of the following characteristics. MSCs can be sourced from various tissue, including umbilical cord, fetal liver, bone marrow, and synovium. MSCs have the ability to develop into practically any end-stage lineage cell, allowing them to seed specific scaffolds. MSCs are potential immune tolerant agents as they have characteristics such as anti-inflammatory, immunoregulatory & immunosuppressive. Several clinical papers back up MSC-based cell therapy's potential efficacy; while its efficacy is still restricted, the results are encouraging.

MSCs have been investigated and used extensively in regenerative medicine. MSCs have moved closer to therapeutic applications for disease therapy and tissue repair in recent years due to improvements in extraction, culture, and differentiation procedures , therefore future research into better biomaterials and effective inducing factors will help MSCs advance in their regenerative medicine applications.

Get Detailed TOC @

Mesenchymal Stem Cells Market Report 2022-2032

Where are the Market Opportunities?

MSC Therapy to Treat Multiple Sclerosis The therapeutic application of MSCs in treating Multiple Sclerosis has proved to provide huge potential by improving clinical symptoms, thereby stabilizing the disease progression. MSCs have properties such as immunomodulator, tissue-protector and repair promotion has proved MSCs to be an attractive therapy option in the treatment of Multiple Sclerosis as well as in other conditions such as inflammation and tissue injury.

MSCs when administered, combat the inflammation in body and regulate the immune system which will further prevent myelin degradation. Clinical trials demonstrating the application of MSCs in Multiple Sclerosis patients have shown increased energy levels, improved flexibility, strength, and mobility. It has also been observed that if MSCs are administered intravenously may have the ability to halt diseases progression for an extended time duration.

MSCs offer intrinsic benefits over hematopoietic stem cells, that MSCs can differentiate into a cell types, release immunoregulatory molecules and promote release of exosome and growth factors

Competitive Landscape The major players operating in the mesenchymal stem cells market are Thermo Fischer Scientific Inc., Merck KGaA (Millipore Sigma), STEMCELL Technologoes Inc., Cytori Therapeutics Inc. (Plus Therapeutics Inc.), Cyagen Biosciences, PromoCell GmbH, Celprogen Inc. Stemedica Cell Technologies Inc., Cell Application Inc., Lonza, Celltex Therapeutics Corporation. These major players operating in this market have adopted various strategies comprising M&A, investment in R&D, collaborations, partnerships, regional business expansion, and new product launches.

Recent Developments

Avoid missing out by staying informed order our report now.

To find more Visiongain research reports on the Pharma sector, click on the following links:

Do you have any custom requirements we can help you with?Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help:dev.visavadia@visiongain.com

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent market intelligence providers around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports, which cover 10-year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets with a lot of synergies. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customised and syndicatedmarket research reportsoffer a bespoke piece of market intelligence customised to your very own business needs.

Contact: Dev Visavadia PR at Visiongain Reports Limited Tel: + 44 0207 336 6100 Email: dev.visavadia@visiongain.com

Read the original post:
Mesenchymal stem cells market is projected to grow at a CAGR of 13.82% by 2032: Visiongain Research Inc - GlobeNewswire

Deciphering the dynamics of the ovarian reserve in cynomolgus monkey through a quantitative morphometric study – EurekAlert

image:Graphical abstract of this study. A total of 18 ovaries from 16 cynomolgus monkeys were collected and separated into five developmental stages: perinatal period (E140, 8-day-old [8 d]), preadolescence (13 years), adolescence (45 years), adulthood (615 years), and perimenopause (1623 years). Immunofluorescent staining and H&E staining of ovaries were performed to investigate the dynamics of the cynomolgus monkey ovarian reserve and the establishment of the primordial follicle pool. Serum samples were collected to analyze the hormone levels. view more

Credit: Science China Press

This study is led by Prof. Hongmei Wang (State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences), Prof. Lan Zhu (Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College), Prof. Xiaokui Yang (Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University), and Dr. Long Yan (State Key Laboratory of Stem Cell and Reproductive Biology, Institute of Zoology, Chinese Academy of Sciences).

Female reproduction and health are highly dependent on ovarian function. Ovarian reserve is a critical indicator of ovarian function. A systematic study of the ovarian reserve covering the human lifespan would benefit the understanding and treatment of reproductive aging under physiological and pathological conditions. However, due to ethical constraints and limited access to intact disease-free human ovarian tissues, research on the ovarian reserve in healthy women throughout their lifespan is limited. Non-human primates share similar genetic and physiological properties with humans and are considered an ideal model for studying the human ovarian reserve covering the lifespan. However, to date, there is no literature on the ovarian reserve covering the lifespan of non-human primates.

Wan Tu et al. used modern stereology techniques to count follicles and revealed the dynamics of the cynomolgus monkey (Macaca fascicularis) ovarian reserve covering its lifespan. The number of primordial follicles decreased with age: perinatal period (1.5 105 on average), preadolescence (1.2 105 on average), adolescence (7.7 104 on average), adulthood (4.3 104 on average) and perimenopause (2.5 103 on average). These results suggested that the ovarian reserve was abundant in the perinatal monkey ovary, then sharply declined during adolescent and adult ovaries, finally exhausted in the perimenopausal monkey ovary.

To investigate the establishment of primordial follicle pool, they performed immunofluorescent staining and H&E staining of perinatal monkey ovaries. The results suggested that the establishment of the primordial follicle pool in cynomolgus monkeys was initiated before E90 and was accomplished in two weeks after birth. Accompanied by the dynamics of ovarian reserve, ovarian fibrosis and oxidative DNA damage level were increased significantly with age. Moreover, they found that the age-related trend in AMH (anti-Mllerian hormone) levels in cynomolgus monkeys was consistent with that in humans, suggesting that AMH could also be a predictor of ovarian reserve in cynomolgus monkeys.

In summary, they depicted the dynamics of the ovarian reserve in cynomolgus monkeys covering their lifespan, provided evidence to show the establishment of the primate primordial follicle pool, and the correlation between the dynamics of ovarian reserve and ovarian microenvironmental changes. This study provided a solid foundation for investigating the mechanisms of ovarian aging and reproductive medicine research.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read this article:
Deciphering the dynamics of the ovarian reserve in cynomolgus monkey through a quantitative morphometric study - EurekAlert

Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event – GlobeNewswire

EDEN PRAIRIE, Minn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced CEO Jeff Ross will present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event. The two-day virtual event held this year on September 28-29, will focus the first day on solid organ transplant (SOT), in particular, kidney transplants, and the second day on the unmet need and innovations in hematopoietic stem cell transplant (HSCT).

Mr. Ross will be presenting at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event on September 28th, 2022 at 10:00 am CT. Registration for the event can be found here.

About Miromatrix Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visitmiromatrix.com.

Investor Contact Greg Chodaczek 347-620-7010 ir@miromatrix.com

Media Contact: press@miromatrix.com

Follow this link:
Miromatrix CEO Jeff Ross to Present at the Innovations in Solid Organ and Hematopoietic Stem Cell Transplant Virtual Event - GlobeNewswire